Kunal Mahajan: Lipoprotein(a) and LDL-C Target Attainment in ACS Patients
Kunal Mahajan, Director and Chief Interventional Cardiologist at Himachal Heart Institute, shared a post on X about a recent article he and his colleagues co-authored, adding:
“Happy to share our study in the Journal of Clinical Lipidology.
In ACS patients treated with triple oral lipid-lowering therapy, lipoprotein(a) increased significantly after ACS, and higher baseline lipoprotein(a) predicted failure to achieve low-density lipoprotein cholesterol less than fifty milligrams per deciliter at one month.”
Title: Changes in Lipoprotein(a) and Their Association With LDL-C in ACS Patients Treated with Triple Oral Lipid-Lowering Therapy
Authors: Kunal Mahajan, Nitin Mahajan, Jai Bharat Sharma, Surender Himral, Tanuj Bhatia, Deep Dutta
Read the Full Article on Journal of Clinical Lipidology
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 17, 2026, 15:49Melissa Hollo: Closing the Gap in Maternal Anemia Care Through HerCare
-
Mar 17, 2026, 15:46Simon Senanu: Rouleaux Formation – When Red Cells Stack Like Coins
-
Mar 17, 2026, 15:45Heghine Khachatryan: Hidden Hematologic Causes of Cryptogenic Stroke
-
Mar 17, 2026, 15:45Wolfgang Miesbach: Six Years of Normal Factor VIII After a Single Gene Therapy in Hemophilia A
-
Mar 17, 2026, 15:44Jan Sloves: Venous Phasicity and the Role of IVC Mechanics
-
Mar 17, 2026, 15:43How Clinicians Navigate the Challenge of Balancing Clotting and Bleeding in CAD – Vasculearn Network
-
Mar 17, 2026, 15:41Beverly G. Tchang: Lipid-Lowering Therapy in Women During Pregnancy and Lactation
-
Mar 17, 2026, 15:34Folusho Adeosun: Raising Fetal Hemoglobin as a Powerful Protective Shield in Sickle Cell Disease
-
Mar 17, 2026, 15:28Aafreen Kotadiya: Why a Great Blood Bank Team is a Rare and Powerful Asset in Transfusion Medicine